CGT6297
CGT6297-25-101
Phase 1 small_molecule active
Quick answer
CGT6297 for PIK3CA Mutations is a Phase 1 program (small_molecule) at Cogent Biosciences with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Cogent Biosciences
- Indication
- PIK3CA Mutations
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active